NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

Matthew Philippe
Executive VP & Head of Investor Relations

All right. Good morning, everybody. Thank you for joining us today for our Annual Investor Day. I’m pleased to have Michael Davidson, our CEO; John Kastelein, our Chief Scientific Officer; and BJ Jones, our Chief Commercial Officer, here with us today speaking, along with many members of our team. Ian Somaiya will also be available for questions afterwards for the presentation.

Before we get started, the fun part, we will be making forward-looking statements today. I would advise everyone to please read our forward-looking statement page, either here in the room or also available online at this time. As we mentioned, today we’ll have Michael being going through a general corporate update and introduction. We’ll have John presenting the science, then we’ll go back to Michael for an update on PREVAIL as well as some of the updates on AD, and then BJ will be going through commercial.

At this time, I’d like to have Michael come up and join us. Michael?

Michael Davidson
CEO, President & Executive Director

Thank you, Matt, and thanks, everyone, for being here. We’re very